Current nonclinical testing paradigm to allow clinical entry for pharmaceutical drug candidates

Paul Baldrick

Open source

DOI
10.1016/j.yrtph.2025.105809
Published
2025-06
Container
Regulatory Toxicology and Pharmacology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.yrtph.2025.105809,
  title = {Current nonclinical testing paradigm to allow clinical entry for pharmaceutical drug candidates},
  author = {Paul Baldrick},
  year = {2025},
  journal = {Regulatory Toxicology and Pharmacology},
  doi = {10.1016/j.yrtph.2025.105809},
  url = {https://doi.org/10.1016/j.yrtph.2025.105809}
}

RIS

TY  - JOUR
TI  - Current nonclinical testing paradigm to allow clinical entry for pharmaceutical drug candidates
AU  - Paul Baldrick
PY  - 2025
JO  - Regulatory Toxicology and Pharmacology
DO  - 10.1016/j.yrtph.2025.105809
UR  - https://doi.org/10.1016/j.yrtph.2025.105809
ER  - 

APA

Baldrick, P. (2025). Current nonclinical testing paradigm to allow clinical entry for pharmaceutical drug candidates. Regulatory Toxicology and Pharmacology. https://doi.org/10.1016/j.yrtph.2025.105809

Source records